CYCN

Cyclerion is a clinical-stage neuropsychiatry name whose reported $2.07M of FY2025 'revenue' is not a business — it reflects legacy license/amendment payments from Akebia on praliciguat (the $1.75M 2024 amendment, $0.5M paid Sept 2025), not product sales. The forward story is CYC-126, an 'individualized therapy' for treatment-resistant depression licensed from MIT in Sept 2025, plus a Jan 2026 option-to-license with Medsteer. Notably R&D expense is just $959K — the MD&A describes 'advancing an integrated clinical, regulatory, and commercial strategy,' but the spend and disclosures point to a pre-clinical program with no human efficacy data in the numbers. That is the definition of an unknowable binary.

The balance sheet cannot fund that ambition. Cash is $3.24M against operating cash burn of -$3.31M — roughly one year of runway. Management states outright it must 'seek additional capital through equity or other financing transactions' and points to a Form S-3 shelf. Critically, because non-affiliate float is under $75M, the baby-shelf rule caps 12-month issuance at one-third of that float; on a $14.9M cap that is only a few million dollars, and it comes via dilution at a depressed price. Shares already grew 59.8% YoY, and the accumulated deficit is -$271M — this equity has been a serial destroyer of capital (net losses of -$51.6M, -$44.1M in 2021-2022).